Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan.
A group of independent FDA advisers voted in favor of a new anti-infective from Astellas Pharma, setting the stage for a likely approval.
Astellas has capped a string of new drug development deals by upping the ante on its pact with South San Francisco-based Cytokinetics. After handing over a $40 million upfront fee for their original 2013 deal, Astellas has come back with $75 million more in near-term financing and more than $600 million in milestones on the table.
Just weeks ago Astellas teamed up with Harvard's Constance Cepko on a new program for a degenerative eye disease. Today it inked a deal with Proteostasis Therapeutics that could be worth up to $1.2 billion while getting Dana-Farber investigators to help hunt down new cancer drugs that can inhibit K-Ras.
In the midst of an unprecedented dealmaking spree that has produced $139 billion in pharmaceutical mergers this quarter alone, one country has been conspicuously absent: Japan. Even such giants as Astellas Pharma and Takeda Pharmaceutical, which have led M&A runs in Japan in the past, have stayed on the sidelines. Why?
Medivation and Astellas Pharma unveiled final results on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of Xtandi (enzalutamide), showing that the drug delayed tumor growth and prolonged the lives of patients with metastatic prostate cancer who previously have not undergone chemotherapy.
Aveo Oncology's long-troubled tivozanib is unlikely to meet its primary endpoint in a study on colorectal cancer, the company said, sending the biotech back to the drawing board after a high-profile failure in kidney cancer.
Xtandi has reached a key milestone: success in a Phase III trial eyeing the drug from Medivation and Astellas as a prechemo treatment for advanced prostate cancer.
Teri Willey has stepped in to take over as vice president of business development and technology transfer at Cold Spring Harbor Laboratory.
Cytokinetics is on a roll. After topping off its long-term heart drug development deal with Amgen last week with a $75 million licensing deal covering Japan, the South San Francisco-based biotech is back with a $490 million licensing and discovery deal with Astellas, which is concentrating on muscle weakness and fatigue.